The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Occurence of other malignancies in patients with CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, gives an overview of a retrospective study investigating the occurrence of other malignancies in other patients with chronic lymphocytic leukemia (CLL). Dr Scarfò reports that chemoimmunotherapy increases the risk of acute myeloid leukemia and myelodysplasia, in particular with the combination of fludarabine, cyclophosphamide and rituximab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Lydia Scarfo, MD, has participated in advisory boards with AbbVie and Janssen and in educational activities with AstraZeneca.
